Injection of large doses of ammonia into rats leads to depletion of brain ATP. However, the molecular mechanism leading to ATP depletion is not clear. The aim of the present work was to assess whether ammoniuminduced depletion of ATP is mediated by activation of the NMDA receptor . It is shown that injection of MK-801, an antagonist of the NMDA receptor, prevented ammoniainduced ATP depletion but did not prevent changes in glutamine, glutamate, glycogen, glucose, and ketone bodies . Ammonia injection increased Na',K+-ATPase activity by 76%. This increase was also prevented by previous injection of MK-801 . The molecular mechanism leading to activation of the ATPase was further studied. Na+,K+-ATPase activity in samples from ammonia-injected rats was normalized by "in vitro" incubation with phorbol 12-myristate 13-acetate, an activator of protein kinase C. The results obtained suggest that ammoniainduced ATP depletion is mediated by activation of the NMDA receptor, which results in decreased protein kinase C-mediated phosphorylation of Na+,K+-ATPase and, therefore, increased activity of the ATPase and increased consumption of ATP.

We have shown previously that chronic hyperammonemia increases, in brain, the polymerization of microtubules that is regulated mainly by the level and state of phosphorylation of microtubule-associated protein 2 (MAP-2). Activation of the N-methyl-D-aspartate (NMDA) receptor dephosphorylates MAP-2. Because we have found that acute ammonia toxicity is mediated by the NMDA receptor, we have tested the effect of high ammonia levels on MAP-2 in brain. Microtubules isolated from rats injected intraperitoneally with 6 mmol/kg ammonium acetate showed a marked decrease of MAP-2. Also, the amount of MAP-2 in brain homogenates, determined by immunoblotting, was markedly reduced, presumably by proteolysis. The content of MAP-2 was decreased by approximately 75% 1-2 h after ammonium injection and returned to normal values after 4 h. Proteolysis of MAP-2 was prevented completely by injection of 2 mg/kg MK-801, a specific antagonist of the NMDA receptor, suggesting that proteolysis is mediated by activation of this receptor. L-Carnitine, which protects rats against ammonia toxicity, also prevented MAP-2 degradation. Because activation of the NMDA receptor increases [Ca2+]i, we determined whether rat brain contains a Ca(2+)-dependent protease that selectively degrades MAP-2. We show that there is a cytosolic Ca(2+)-dependent protease that degrades MAP-2, but not other brain proteins. The protease has been identified tentatively as calpain I, for it is inhibited by a specific inhibitor of this protease. Our results suggest that ammonium injection activates the NMDA receptor, leading to an increase in [Ca2+]i, which activates calpain I. This, in turn, selectively degrades MAP-2.(ABSTRACT TRUNCATED AT 250 WORDS)

We have proposed that acute ammonia toxicity is mediated by activation of the N-methyl-D-aspartate type of glutamate receptors. MK-801, a selective antagonist of these receptors, prevents death of animals induced by acute ammonia intoxication as well as ammonia-induced depletion of ATP. It seems therefore that, following activation of the N-methyl-D-aspartate receptors, the subsequent events in ammonia toxicity should be similar to those involved in glutamate neurotoxicity. As it has been shown that inhibitors of nitric oxide synthetase such as nitroarginine prevent glutamate toxicity, we have tested whether nitroarginine prevents ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. It is shown that nitroarginine prevents partially (approximately 50%), but significantly death of mice induced by acute ammonia intoxication. Nitroarginine also prevents partially ammonia-induced depletion of brain ATP. It also prevents completely the rise in glucose and pyruvate and partially that in lactate. Injection of nitroarginine alone, in the absence of ammonia, induces a remarkable accumulation of glutamine and a decrease in glutamate. The results reported indicate that nitroarginine attenuates acute ammonia toxicity and ammonia-induced alterations in brain energy metabolites. The effects of MK-801 and of nitroarginine are different, suggesting that ammonia can induce nitric oxide synthetase by mechanisms other than activation of N-methyl-D-aspartate receptors.

Hyperammonemia increases the polymerization of brain microtubules, which is controlled by the binding of microtubule-associated protein (MAP) 2; binding of MAP-2 is, in turn, regulated by phosphorylation. We have found that the binding of MAP-2 to tubulin is greatly increased by hyperammonemia, however, the brain content of MAP-2 is not affected. Microtubules isolated from hyperammonemic rats contained approximately twice the MAP-2/mg microtubular protein that of microtubules isolated from control animals. MAP isolated from brain microtubules of hyperammonemic rats stimulated the polymerization of tubulin more than MAP isolated from control animals. This appears to be due to the increased content of MAP-2. In vitro phosphorylation, using brain homogenates, showed that protein-kinase-C-dependent phosphorylation of MAP-2 was markedly decreased in hyperammonemic rats. Hyperammonemia also affected the intracellular distribution of brain protein kinase C; its content in the cytosol increased about 23%, while in membranes it decreased by 46 %. The possible role of decreased protein-kinase-C-dependent phosphorylation on the increased binding of MAP-2 to tubulin and in the increased polymerization of microtubules in the brain of hyperammonemic rats is discussed.Hepatic encephalopathy is one of the main causes of death in western countries ; however, in spite of much work, its pathogenesis is not well understood and several hypotheses have been proposed as explanations for its effects. Hyperammonemia is considered one of the most important factors responsible for the mediation of hepatic encephalopathy. Elevated levels of blood ammonia accompany a number of human liver diseases, including cirrhosis and acute liver failure. A fivefold-tenfold increase in normal ammonia concentrations in the blood induces toxic effects in most animal species, with functional disturbances in the central nervous system. However, the molecular basis underlying the effects of ammonia on the brain function remains unclear.We have found that chronic hyperammonemia increases the tubulin content in certain areas of the brain [l-31. In the axon, microtubules serve as the main path for organelle transport, including that of neurosecretory vesicles ; therefore, an alteration in the microtubules could be involved in the neurologic impairment found in hyperammonemia.The synthesis of tubulin in cultured cells is regulated by the level of free tubulin; a decreased level induces synthesis, while an increased level inhibits synthesis [4]. Tubulin polymerization in brain is controlled mainly by the binding of microtubule-associated protein (MAP) 2 and z proteins, which stimulate polymerization. The ability of these proteins to bind tubulin is, in turn, controlled by the phosphorylation of MAP-2 and t [5-61. In studies aimed to clarify the mechanism by which high ammonia levels induce tubulin synthe- sis, we found that chronic hyperammonemia increases the polymerization of microtubules and that changes in polymerization precede changes in tubulin synthesis [...

A protein-free diet causes a paradoxical increase of blood ammonia levels that seems to be due to decreased liver content of acetylglutamate, the physiological activator of carbamylphosphate synthetase. The purpose of this study was to assess whether oral administration to rats of carbamylglutamate, a metabolically stable activator of carbamylphosphate synthetase, could decrease the blood ammonia levels increased by the protein-free diet. We show that ingestion of moderate doses of carbamylglutamate increased about sixfold the liver content of carbamylphosphate synthetase activators and restores to normal values the blood ammonia levels. Excess ammonia is eliminated in urine as urea. These results indicate that carbamylglutamate, which is not toxic, could be useful in the treatment of hyperammonemia, especially in cirrhosis.